Amycretin

Last Updated: July 2026

Amycretin — which has since been assigned the international nonproprietary name zenagamtide — is Novo Nordisk's investigational, first-in-class unimolecular GLP-1 and amylin receptor agonist: a single molecule that activates both receptors, folding the amylin satiety pathway and the GLP-1 pathway into one agent (rather than combining two drugs as in CagriSema). Novo moved both the oral (once-daily) and subcutaneous (once-weekly) formulations into Phase 3 during Q1 2026, on the strength of early data showing roughly 22% weight loss over 36 weeks subcutaneously and about 13% over 12 weeks orally. It is not approved and not commercially available, and approval is not expected before the end of the decade.

What is Amycretin and why does the GLP-1/amylin combination matter?

Amycretin adds amylin's satiety mechanism to GLP-1's appetite and glucose effects in a single molecule — amylin (the pathway behind cagrilintide and pramlintide) is a genuinely different lever that may deepen and sustain weight loss. Its dual oral/subcutaneous development is unusual and commercially significant.

What does the clinical evidence show?

Early-phase trials (published in The Lancet) showed striking weight loss — up to ~22% at 36 weeks for subcutaneous and ~13% at 12 weeks for oral — but these are early, relatively small, short studies, with Phase 3 still to confirm whether the curves hold. A Phase 2 in type 2 diabetes also showed significant weight loss and HbA1c reduction. Evidence level: Phase 1b/2a–Phase 2 (early); Phase 3 underway — not approved.

What are the known side effects and safety concerns?

The most frequent reported effects were gastrointestinal, consistent with the GLP-1 component; the full safety profile is not yet established at Phase 3 scale. Evidence level: Early-phase.

What is the regulatory status, and why is verification critical here?

Amycretin is investigational and not available by any legitimate route — so any "amycretin" sold through research-chemical vendors is not from Novo Nordisk and is almost certainly counterfeit or mislabeled. For a compound this early and this in-demand, independent identity confirmation is the only meaningful check. See the legal status guide.

How does Peptigrity verify Amycretin?

Peptigrity buys any marketed "amycretin" anonymously and submits it to independent ISO-accredited labs for HPLC and mass-spec — the only way to know whether an unapproved, unavailable compound is what the label claims. Results appear above; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical advice. Amycretin is investigational and not approved. Any research-market material is unverified. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.